ResQ Pharma, Inc
ResQ Pharma, Inc
  • Home
  • About Us
  • Background
  • Target Indications
  • History
  • Contact
  • More
    • Home
    • About Us
    • Background
    • Target Indications
    • History
    • Contact
  • Home
  • About Us
  • Background
  • Target Indications
  • History
  • Contact

LOCAL ANESTHETIC SYSTEMIC TOXICITY (LAST)

NOTE:

LipidRescue® is an investigational drug; the safety and efficacy of the drug have not been approved or authorized by FDA.  LipidRescue® is a proposed proprietary name that is subject to FDA approval.

WHAT IS LAST?

LAST is a life-threatening medical complication that occurs when local anesthetics enter the circulation producing potentially severe cardiac and neurological toxicity. It can occur whenever and wherever local anesthetics are used and can result in seizures, cardiovascular instability (irregular heart rhythm, low blood pressure, etc.) and even cardiac arrest. Clinical experience and laboratory data indicate that LipidRescue can treat LAST.


LAST IS THE FIRST INDICATION FOR WHICH RESQ SEEKS FDA APPROVAL OF A LIPIDRESCUE® CONVENIENCE KIT

HOW CAN LIPIDRESCUE® THERAPY HELP?

LAST is a medical emergency that requires immediate care.  Basic and advanced life support, includes:


  • Airway management to assure oxygenation and ventilation 
  • Drugs to treat seizures and support blood pressure
  • CPR AS NEEDED
  • LipidRescue® TO POTENTIALLY REVERSE  TOXICITY

More information about LAST

How often does LAST occur?

  • Roughly 1-2 cases per 1,000 regional anesthetics
  • This is roughly 100 times more frequent than malignant hyperthermia

Where does LAST Occur?

  • Operating rooms, other ("offsite") hospital settings
  • Surgicenters and urgent care centers
  • Doctors' offices
  • Literally, anywhere local anesthetics are used

What is ResQ Pharma doing?

  • Seeking FDA approval of a LAST kit
  • Kit will improve access to an effective treatment for LAST
  • Promoting education to prevent LAST and improve safety
  • Improving treatment options for LAST 

LAST-Related Videos

Fadzlon lecture series: Local Anesthetic Systemic Toxicity

LipidRescue® in a rat model

Cardiac Arrest: The Role of LipidRescue

  

LipidRescue® is an investigational drug; the safety and efficacy of the drug have not been approved or authorized by FDA. 

LipidRescue® is a proposed proprietary name that is subject to FDA approval. 


Website designed by JDW

Copyright © 2021 ResQ Pharma, Inc - All Rights Reserved.


Powered by GoDaddy